Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

falsified_medicines

Counterfeit drugs – countering the lies

February 4, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Counterfeit drugs, IP, counterfeit medicines, falsified medicines, intellectual property, law, legal, patent

As the Falsified Medicines Directive comes into effect in February 2019, Louis Goss fact checks ‘common sense’ claims on counterfeit …
Feature
janssen_latest_logo_on_sign_closer

Janssen seals global inherited retinal disease partnership with gene therapy firm MeiraGTx

February 1, 2019 Medical Communications, Research and Development, Sales and Marketing Janssen, MeiraGTx, eye care, gene therapy, pharma

In a bid to boost its portfolio in the eye care space, Janssen has announced a global partnership with clinical-stage …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

February 1, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, England, NHS, Purdue, Vertex, insys, israel, oncology, pharma, top 10

Scandal dominated this week’s news after Sunrise Lee, a stripper turned Insys sales rep was alleged to have given a …
News
both_together

Repurposed drugs: The Supreme Court deals a blow to patentees

January 31, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Supreme Court, drug repurposing, feature, patents, pharma

Second medical use patents protect the discovery that an existing drug is effective to treat a new condition. But, following …
Feature
janssen_latest_logo_on_sign

Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer

January 31, 2019 Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer

Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …
News
6813384933_1fb31d73fb_z

Health Secretary pledges to end transmission of HIV in England by 2030

January 31, 2019 Medical Communications, Research and Development 2030, AIDS, England, HIV, UN, health

Through better prevention, detection and treatment, Health Secretary Matt Hancock has pledged to end transmission of HIV in England by …
News
richard_ridinger

Richard Ridinger resigns from CEO position at Lonza causing shares to plummet

January 30, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Lonza, Marc Funk, Richard Ridinger, Switzerland

Richard Ridinger, the CEO of Swiss biotechnology firm Lonza Group, will step down from his position in March of this …
Appointment
pharmafocus_janfeb_2019_cover

Read Pharmafocus January/February 2019 edition online now!

January 30, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Cancer, Counterfeit drugs, NHS, Pharmafocus, WHO, brexit, pharma, vaccines

We’re slowly edging towards warmer months, but the New Year brings more than just the promise of more amicable weather; …
News
takeda_usa_pharmaceuticals_u

Takeda’s dengue vaccine proves efficacious in massive Phase 3 trial

January 30, 2019 Research and Development Dengue fever, TAK-003, Takeda, Vaccine, dengue, health, infectious diseases

Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing …
News
cancer-cells-541954_960_720

Israeli biotech claims it has developed cure for cancer

January 30, 2019 Research and Development Cancer, MuTaTo, biotech, israel, lung cancer, oncology

An Israeli biotech has claimed that it has developed a complete cure for cancer. Speaking to the Jerusalem Post, Dan …
News
shutterstock_38078521

Roche pulls plug on Alzheimer’s drug after Phase 3 failure

January 30, 2019 Research and Development AC Immune, Alzheimer's, Roche, crenezumab, pharma

Roche has announced that it is to terminate two Phase 3 studies investigating the efficacy of its anti-beta-amyloid molecule crenezumab …
News

ABPI warns of skills shortage in UK caused by lack of STEM grads and Brexit

January 30, 2019 Research and Development ABPI, UK, eomployment, skills, stem, work

The UK is falling behind Europe and the rest of the world in regards to the number of students studying …
News
shutterstock_168864905

Destiny Pharma secures £1.6m grant to fight ‘superbugs’ and antimicrobial resistance

January 29, 2019 Manufacturing and Production, Research and Development Destiny Pharma, antimicrobial resistance, pharma

UK biotech Destiny Pharma has secured £1.6 million in funding to further its research into the prevention and elimination of …
News
alexander_hardy

Alexander Hardy returns to Genentech as new CEO

January 28, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Genentech, Roche, appointment, pharma

Genetech, the biotech subsidiary of Swiss firm Roche, has named its new CEO, revealing that Alexander Hardy will be returning …
News

Philip Hampton to step down from chairman role at GSK

January 28, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, UK, appointment, pharma

Sir Philip Hampton is stepping down from his role as non-executive chairman of British multinational GlaxoSmithKline. The resignation comes just …
Appointment
The Gateway to Local Adoption Series

Latest content

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026

Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer

March 23, 2026